NASDAQ:PRTA Prothena Q3 2026 Earnings Report $8.61 +0.13 (+1.53%) Closing price 04:00 PM EasternExtended Trading$8.62 +0.01 (+0.12%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Prothena EPS ResultsActual EPSN/AConsensus EPS -$0.21Beat/MissN/AOne Year Ago EPSN/AProthena Revenue ResultsActual RevenueN/AExpected Revenue$9.58 millionBeat/MissN/AYoY Revenue GrowthN/AProthena Announcement DetailsQuarterQ3 2026Date11/5/2026TimeAfter Market ClosesConference Call DateThursday, November 5, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Prothena Earnings HeadlinesProthena (NASDAQ:PRTA) Stock: Insider William Scully Purchases 100,000 SharesOctober 8 at 4:22 AM | americanbankingnews.comProthena (NASDAQ:PRTA) Stock: Insider William Scully Acquires 103,500 SharesOctober 1, 2026 | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 8 at 1:00 AM | Porter & Company (Ad)Prothena owner buys 103,500 sharesSeptember 30, 2026 | americanbankingnews.comProthena (NASDAQ:PRTA) Stock Crosses Below 200-Day Moving Average - Here's What HappenedSeptember 29, 2026 | americanbankingnews.comProthena Corp Public Ltd Insider Bought Shares Worth $843,460, According to a Recent SEC FilingSeptember 21, 2026 | marketscreener.comMSee More Prothena Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prothena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prothena and other key companies, straight to your email. Email Address About ProthenaProthena (NASDAQ:PRTA) is a clinical-stage biotechnology company focused on discovering and developing therapies for diseases caused by protein misfolding or abnormal protein accumulation. Its research programs target neurological and systemic disorders, including Alzheimer’s disease, Parkinson’s disease, and transthyretin amyloidosis. The company’s pipeline has included PRX012, an investigational next-generation antibody targeting amyloid beta for Alzheimer’s disease; prasinezumab, an anti-alpha-synuclein antibody being developed for Parkinson’s disease through a collaboration with Roche; and birtamimab, an investigational treatment designed to target misfolded light chains associated with AL amyloidosis. These candidates remain subject to clinical testing and regulatory review, and Prothena does not have a broad portfolio of commercially marketed products. Prothena was established in 2012 following the separation of neuroscience assets from Elan Corporation. The company is incorporated in Ireland and conducts research and development through operations and partnerships serving international markets. Its business model centers on applying expertise in protein biology and antibody development to create potential treatments for serious diseases with limited therapeutic options.View Prothena ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
